#checkmate214 — Public Fediverse posts

4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter

Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214

13/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🔬Common tox in pivotal P3 #CHECKMATE214 trial of dual ICI combo🔬
🔸Fatigue
🔹Pruritus
🔸Diarrhea
🔹Rash
🔸Nausea

13/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🔬Common tox in pivotal P3 #CHECKMATE214 trial of dual ICI combo🔬
🔸Fatigue
🔹Pruritus
🔸Diarrhea
🔹Rash
🔸Nausea

6/ #TumorBoardTuesday #BonumCE #OncTwitter #NephTwitter #MedTwitter #RenalCell

✳️Dual ICI combo (ipi + nivo) also approved tx option

💎#CheckMate214 - ipi + nivo vs sunitinib
✅Longest follow-up in frontline RCC (>5 years)
✅OS and PFS favor combo tx in int/poor risk pts

5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214

💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC